Cargando…

IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS

INTRODUCTION: T cell dysfunction contributes to immune escape in patients with cancer and is particularly severe in CNS tumors. T cell sequestration is a contributing mechanism of T cell lymphopenia and lymphoid organ contraction occurring in treatment naive patients and mice with Glioblastoma. Our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Zach, Fecci, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Immunology/Immunotherapy - IMMU
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259901/ http://dx.doi.org/10.1093/neuonc/noad073.199

Ejemplares similares

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

IMMU-16. IDENTIFICATION OF TUMOR REJECTION ANTIGENS FOR PRECISION ADOPTIVE CELLULAR THERAPY FOR PEDIATRIC GLIOMAS
por: Trivedi, Vrunda, et al.
Publicado: (2023)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT
por: Najem, Hinda, et al.
Publicado: (2023)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
por: Harvey, Kyra, et al.
Publicado: (2023)

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
por: Hoare, Owen, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
por: Mahdi, Jasia, et al.
Publicado: (2023)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

IMMU-23. RESEARCH ON MULTI-ANTIGEN T CELL INFUSION AGAINST NEURO-ONCOLOGIC DISEASE (ReMIND)
por: Cruz, Conrad Russell, et al.
Publicado: (2023)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
por: Figg, John, et al.
Publicado: (2023)

IMMU-22. ALLOGENEIC NK CELLS SECRETING IL15 AND RESISTANT TO TGF-β Show Antitumor Activity Against Gliobastoma
por: Muniraj, Nethaji, et al.
Publicado: (2023)

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
por: Thompson, Eric, et al.
Publicado: (2023)

IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS
por: Lin, Frank, et al.
Publicado: (2023)

IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
por: Owens, Geoffrey, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
por: Myers, Carrie, et al.
Publicado: (2023)

IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
por: Marquardt, Viktoria, et al.
Publicado: (2023)

EPEN-13. PATTERN OF RELAPSE IN POSTERIOR FOSSA EPENDYMOMA GROUP A
por: Bajin, Inci Yaman, et al.
Publicado: (2023)

IMMU-03. CHARACTERIZING THE IMMUNE MICROENVIRONMENT OF PEDIATRIC BRAIN TUMORS
por: Galvin, Robert, et al.
Publicado: (2021)

IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS
por: Beck, Pengbo, et al.
Publicado: (2021)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

IMMU-07. “STROKE MIMICS” ARE NOT BENIGN IN IMMUNOCOMPROMISED CHILDREN
por: Mahdi, Jasia, et al.
Publicado: (2021)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2021)

SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
por: Lorrey, Selena, et al.
Publicado: (2023)

IMMU-10. USE OF A SINGLE PEPTIDE CHECKPOINT INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2021)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

IMMU-13. CUSTOMIZABLE MULTI-LAMELLAR RNA-NANOPARTICLES FOR PEDIATRIC GLIOMA
por: Mendez-Gomez, Hector, et al.
Publicado: (2021)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)

IMMU-11. CLINICAL UPDATES AND CORRELATIVE FINDINGS FROM THE FIRST PATIENT WITH DIPG TREATED WITH INTRACRANIAL CAR T CELLS
por: Vitanza, Nicholas, et al.
Publicado: (2021)

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION
por: Wilkinson, Daniel, et al.
Publicado: (2023)

IMMU-15. QUANTIFYING INTRATHECAL DRUG DELIVERY UTILIZING PROGRAMMABLE VENTRICULOPERITONEAL SHUNTS
por: McThenia, Sheila, et al.
Publicado: (2021)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5upgohce8r74gciupntljt17ls